Assignee
ARCUS BIOSCIENCES INC
US·37 granted patents·18 pending applications·97 citations·filing 2017–2025
Top patents by PatentIndex Score
55 records- 0198US11001603B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2020·Granted May 11, 2021·13 cites·1 claims
- 0296US11633416B1Oral formulations of CD73 compoundsARCUS BIOSCIENCES INC·Filed 2021·Granted Apr 25, 2023·4 cites·24 claims
- 0396US10239912B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 26, 2019·23 cites·47 claims
- 0495US11667662B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2021·Granted Jun 6, 2023·4 cites·9 claims
- 0595US10981944B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Apr 20, 2021·11 cites·20 claims
- 0694US12168023B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Granted Dec 17, 2024·1 cites·24 claims
- 0794US11787762B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2022·Granted Oct 17, 2023·2 cites·26 claims
- 0893US11407712B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2αARCUS BIOSCIENCES INC·Filed 2021·Granted Aug 9, 2022·3 cites·15 claims
- 0992US12145901B1Process for preparing tetralin compoundsARCUS BIOSCIENCES INC·Filed 2022·Granted Nov 19, 2024·2 cites·25 claims
- 1092US10399962B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Sep 3, 2019·13 cites·25 claims
- 1191US11819512B2Solid forms of a CD73 inhibitor and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Nov 21, 2023·5 cites·17 claims
- 1290US11649261B2Crystalline forms of a CD73 inhibitor and uses thereofARCUS BIOSCIENCES INC·Filed 2021·Granted May 16, 2023·5 cites·23 claims
- 1388US12195447B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2021·Granted Jan 14, 2025·1 cites·2 claims
- 1487US11072597B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2019·Granted Jul 27, 2021·3 cites·14 claims
- 1586US12459967B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Nov 4, 2025·0 cites·11 claims
- 1686US12103907B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2023·Granted Oct 1, 2024·0 cites·1 claims
- 1785US11058704B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2017·Granted Jul 13, 2021·4 cites·25 claims
- 1884US11820824B2Antibodies to TIGITARCUS BIOSCIENCES INC·Filed 2021·Granted Nov 21, 2023·1 cites·16 claims
- 1983US2025319113A1Inhibitors of adenosine 5'-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2082US2025214930A1Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2179US11267845B2Inhibitors of CD73-mediated immunosuppressionARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 8, 2022·1 cites·32 claims
- 2279US11045472B2Quinazoline-pyridine derivatives for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Jun 29, 2021·1 cites·20 claims
- 2378US12195482B1Compounds as inhibitors of AXLARCUS BIOSCIENCES INC·Filed 2024·Granted Jan 14, 2025·0 cites·2 claims
- 2473US12281136B2Crystalline forms of a CD73 inhibitor and uses thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Apr 22, 2025·0 cites·19 claims
- 2572US12415854B2Antibodies to TIGITARCUS BIOSCIENCES INC·Filed 2023·Granted Sep 16, 2025·0 cites·19 claims
- 2672US12384773B2Thiazole compounds and methods of use thereofARCUS BIOSCIENCES INC·Filed 2024·Granted Aug 12, 2025·0 cites·14 claims
- 2770US11970543B2Anti-CD39 antibodies and use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Apr 30, 2024·0 cites·13 claims
- 2869US2025230173A1Salt forms of an axl inhibitorARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2968US2025084178A1Anti-cd39 antibodies and use thereofARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3067US2023416277A1Compounds as inhibitors of axlARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3166US2023338377A1Dosing with an azolopyrimidine compoundARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3264US2024180947A1Lyophilized formulations of cd73 compoundsARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3362US11478479B2Dosing with an azolopyrimidine compoundARCUS BIOSCIENCES INC·Filed 2019·Granted Oct 25, 2022·0 cites·25 claims
- 3462US2025011318A1Cbl-b inhibitors and methods of use thereofARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3562US2025179176A1Anti-tigit antibodies and uses of the sameARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3662US2024425497A1Cbl-b Inhibitors and Methods of Use ThereofARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3761US2026028336A1Cbl-b inhibitors and methods of use thereofARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3860US12071411B2Inhibitors of HIF-2α and methods of use thereofARCUS BIOSCIENCES INC·Filed 2022·Granted Aug 27, 2024·0 cites·31 claims
- 3960US11993584B2Solid forms of an azolopyrimidine compoundARCUS BIOSCIENCES INC·Filed 2019·Granted May 28, 2024·0 cites·21 claims
- 4057US2024124490A1Inhibitors of hpk1 and methods of use thereofARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4155US12453738B2Treatment of oncogene-driven cancersARCUS BIOSCIENCES INC·Filed 2020·Granted Oct 28, 2025·0 cites·8 claims
- 4255US2025375447A1Treatment of cancer utilizing an identified adenosine fingerprintARCUS BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4354US2024226115A1Axl inhibitor compoundsARCUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4453US2024246967A1Axl compoundsARCUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4553US2026042777A1Piperidylurea compounds and methods of use thereofARCUS BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4652US12310965B2Treatment of cancer utilizing an identified adenosine fingerprintARCUS BIOSCIENCES INC·Filed 2020·Granted May 27, 2025·0 cites·8 claims
- 4752US11931343B2CD73 inhibitorsARCUS BIOSCIENCES INC·Filed 2019·Granted Mar 19, 2024·0 cites·11 claims
- 4851US2022235031A1Processes for preparing aminopyrimidine compoundsARCUS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4951US2023024438A1Inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 5050US12226425B2Inhibitors of ARG1 and/or ARG2ARCUS BIOSCIENCES INC·Filed 2019·Granted Feb 18, 2025·0 cites·11 claims
Showing the top 50 of 55 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →